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Background: Diabetes is associated with a higher risk for adverse cardiovascular outcomes. To improve the health
outcomes of patients with type 2 diabetes (T2DM), the American Diabetes Association (ADA) recommended target
goals for the improvement of glycemic control and the reduction of cardiovascular risk factors associated with the
disease. This retrospective analysis calculated the absolute benefit increase (ABI) of using exenatide once weekly
(QW), a glucagon-like peptide-1 (GLP-1) receptor agonist, vs an oral glucose-lowering medication or insulin glargine
to achieve ADA-recommended goals. The number needed to treat (NNT) to achieve these goals was also calculated
and provides a useful clinical metric for comparing potential therapies from different drug classes.
Methods: Patient data from three double-blind or open label, 26-week, randomized, controlled trials were
retrospectively analyzed separately. ABI and NNT were calculated by comparing the percentage of patients treated
with exenatide QW (N = 641) vs metformin (N = 246), sitagliptin (N = 329), pioglitazone (N = 328), or insulin
glargine (N = 223), who achieved a single glycemic, weight, blood pressure, or lipid goal or a composite of these
recommended goals, during the DURATION-2, -3, and -4 clinical trials.
Results: Significant ABIs favoring exenatide QW over all four glucose-lowering medications were observed for at
least one HbA1c glycemic goal. NNTs of 4 and 5 were calculated when exenatide QW was compared to sitagliptin
for attaining HbA1c goals of <7.0% and ≤6.5%, respectively. Additionally, significantly more patients using exenatide
QW compared to sitagliptin, pioglitazone, or insulin glargine attained the composite goal of HbA1c <7% or ≤6.5%,
without weight gain or hypoglycemia. Exenatide QW was also favored over sitagliptin and insulin glargine for the
achievement of the composite goals of HbA1c <7% (or ≤6.5%), systolic blood pressure <130 mm Hg, and
low-density lipoprotein <2.59 mmol/L. For most goals, exenatide QW and metformin had similar effects in
treatment naïve patients.
Conclusions: This analysis assessed the between-therapy differences in achieving therapeutic goals with therapies
commonly used for glycemic control in patients with T2DM. In clinical trials, exenatide QW assisted more patients
in reaching the majority of ADA-recommended therapeutic goals than treatment with sitagliptin, pioglitazone,
or insulin glargine.
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Although the primary goal in treatment of type 2 diabetes
mellitus (T2DM) is the reduction of hyperglycemia, signifi-
cant benefits of glycemic control on cardiovascular disease
(CVD) in patients with T2DM were observed during the
UK Prospective Diabetes Study (UKPDS), which showed a
14% decrease in the risk of myocardial infarction and 12%
decrease in risk of stroke for each 1% decrease in glycated
hemoglobin A1c (HbA1c) [1]. While reduction of hyper-
glycemia is clearly beneficial, avoidance of hypoglycemia is
also a critical concern, as severe hypoglycemia was associ-
ated with an increased risk of death during the ACCORD
study [2].
Long-term management of patients with T2DM should
target not only glycemic control but also cardiovascular
(CV) risk factors such as blood pressure, body weight, and
lipids. The Steno-2 study examined a multifactorial ap-
proach to diabetes treatment, targeting HbA1c, blood
pressure, lipids, and lifestyle modifications in an intensive
intervention to prevent CVD in patients with T2DM [3,4].
Compared to conventional therapy, intensive multifactor-
ial intervention reduced the risk of CV and microvascular
events by approximately 50%. Based on these and other
well-controlled and uncontrolled clinical studies, (Steno-2
[4], ADVANCE [5], ACCORD [6], UKPDS [7,8], DCCT
[9], The Kumamoto Study [10] and others [11]) the
American Diabetes Association (ADA) developed guide-
lines providing treatment goals intended to offer health
benefits for patients with T2DM who are able to achieve
these goals (Table 1) [11].
The GLP-1 receptor agonist, exenatide, is a synthetic
peptide that has been shown not only to reduce hyper-
glycemia in patients with T2DM but also to improve bodyTable 1 Therapeutic goals explored in the analysis
Selected ADA goals Composite of Selected ADA Goals
HbA1c <7.0% HbA1c <7.0%, no weight gain,
and no hypoglycemia†
*HbA1c ≤6.5% HbA1c ≤6.5%, no weight gain,
and no hypoglycemia†
**FBG <6.99 mmol/L HbA1c <7.0%, SBP <130 mm Hg,
and LDL <2.59 mmol/L
No weight gain HbA1c ≤6.5%, SBP <130 mm Hg,
and LDL <2.59 mmol/L
Any weight loss
No hypoglycemia†
SBP <130 mm Hg
LDL <2.59 mmol/L
*Actual ADA goal is <6.5% if it can be achieved without significant hypoglycemia.
**Not an ADA goal (diabetes diagnosis).
†Hypoglycemia is defined as documented blood glucose <3 mmol/L (<54 mg/dL).
Glucose conversion factor, 0.05551; LDL conversion factor, 0.02586.
FBG, fasting blood glucose; LDL, low density lipoprotein cholesterol; SBP,
systolic blood pressure.weight, blood pressure, and lipid profiles [12-16]. Exenatide
twice daily has been shown to not increase the risk of CV
events in a pooled analysis of clinical trial data.[17] A data-
base analysis using the real-world data has demonstrated
that exenatide twice daily treatment was associated with a
lower risk of CVD events and hospitalizations than treat-
ment with other glucose-lowering therapies.[18] The most
recently approved formulation of exenatide, exenatide once
weekly (QW) for subcutaneous injection, provides a slow
release of exenatide from poly-(d,l-lactide-co-glycolide)
microspheres, allowing weekly dosing [19]. Head-to-head
comparisons have been made between exenatide QW and
other GLP-1 receptor agonist therapies such as exenatide
twice daily and liraglutide [20-22], as well as non-GLP-1
receptor agonist therapies such as metformin, sitagliptin,
pioglitazone, and insulin glargine [23-25].
In addition to the parameters measured in the primary
studies, measures that allow simplified comparisons of
the ability of two different therapies to assist patients
in reaching a treatment goal are of value. The number
needed to treat (NNT) is one such measure that reflects
the number of patients a clinician needs to treat with a
particular therapy instead of another therapy (or compared
to a control) to allow one additional patient to achieve a
treatment goal. The NNT is calculated by comparing the
relative percentages of patients reaching a treatment goal
in each therapeutic group, also called the absolute benefit
increase (ABI) [26-28].
The purpose of this analysis was to compare exenatide
QW with several commonly prescribed therapies from
other drug classes to assess the ABI and the associated
NNT for achieving a clinically beneficial endpoint, defined
as achieving a single or composite of ADA-recommended
goals.
Methods
Data from the intent-to treat (ITT) population of 3 ran-
domized, controlled, 26-week, Phase 3 studies (DUR-
ATION-2, -3, and -4) were retrospectively analyzed
separately [23-25]. The ITT population was defined as pa-
tients receiving at least one dose of the randomized study
medication. Eligible patients in the trials had T2DM and
were at least 18 years of age with a baseline HbA1c of 7.1
to 11.0%, a body mass index of 25-45 kg/m2, and a history
of stable body weight prior to the screening visit. Each
trial was performed in accordance with the ethics princi-
ples stated in the Declaration of Helsinki [29]. An ethics
review board reviewed each study protocol before trial ini-
tiation and patients provided written consent before any
procedure was performed. The studies are registered with
ClinicalTrials.gov, clinical trial numbers NCT00637273,
NCT00641056, and NCT00676338.
In all trials, standard doses of medications were ad-
ministered according to local label approval. Patients in
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dose of metformin as background therapy and were ran-
domized to receive 2 mg of exenatide QW, 100 mg/day
oral sitagliptin, or 45 mg/day oral pioglitazone for
26 weeks. In the open-label, DURATION-3 study, patients
using metformin with or without sulfonylurea as a back-
ground therapy were randomized to receive either 2 mg
of exenatide QW or once daily insulin glargine, titrated to
fasting blood glucose concentrations of 4.0 to 5.5 mmol/L,
for 26 weeks. It was recommended that patients using
sulfonylurea reduce their dose if confirmed hypoglyce-
mia occurred. In the double-blind DURATION-4 study,
drug-naïve patients were randomized to 2 mg of exenatide
QW, 2000 mg/day metformin, 100 mg/day sitagliptin, or
45 mg/day pioglitazone for 26 weeks. Metformin and pio-
glitazone dosages were increased in weekly increments up
to target doses; metformin could be increased to 2500 mg/
day depending on glycemic control. Patient descriptions,
randomization, and procedures were described in detail
previously [23-25].
The attainment of target goals was used as surrogate end-
points for beneficial outcomes (Goalx) and included three
single glycemic goals and four composite goals (Table 1).
The ABI and NNT for the single components of the com-
posite goals such as weight loss (or no weight gain), systolic
blood pressure (SBP), low-density lipoprotein (LDL) choles-
terol, and lack of hypoglycemia (hypoglycemia defined as
documented blood glucose <3 mmol/L [54 mg/dL]) were
also calculated. To quantitate the ABI for each selected
goal, the percentage of ITT patients in either the exenatide
QW or a comparator arm in each study who were not at
the indicated goal at baseline but who reached the goal at
endpoint (26-weeks) was calculated. The ABI was com-
puted as:
ABI ¼ % exenatide QW patients reaching Goalx
 % comparator patients reaching Goal
Individual patient data was used in the analysis. The
last post-baseline data were used to determine achieve-
ment of specific goals. Subjects with no post-baseline mea-
surement were considered to have not reached the goal at
endpoint.
The NNT indicates the number of patients that would
need to be treated with exenatide QW vs a comparator
therapy in order to have one additional patient reach a
particular target goal. The NNT was calculated as 1/ABI
and rounded to next highest integer. Confidence inter-
vals of the NNT were calculated by taking the recipro-
cals of the values defining the 95% confidence interval
(CI) for the ABI and rounding to the next highest inte-
ger [27]. The sign and magnitude of the NNT were used
to determine the extent of the benefit (or lack of benefit) of
treatment with exenatide QW. A positive NNT indicatedan overall benefit in achieving a goal with exenatide QW
use and a negative NNT number indicated the benefit of
the comparator. In addition, the smaller the absolute NNT




Across each individual study, the baseline characteristics
for each therapeutic arm were generally similar (Table 2).
However, all three DURATION studies had a slightly differ-
ent population of patients. All patients in DURATION-2
were treated with concomitant metformin therapy whereas
patients in DURATION-3 were treated with metformin
with or without a sulfonylurea; patients in DURATION-4
were drug-naïve and suboptimally controlled with diet
and exercise. The duration of diabetes was shorter in
DURATION-4 compared to the other two studies. Add-
itionally, the ethnic backgrounds were slightly different
among the studies. There were more Black and Hispanic
patients and fewer White patients in DURATION-2 than
in DURATION-3 or -4, and there were fewer Asian pa-
tients in DURATION-3 than in the other two studies.
Exenatide QW vs metformin
Metformin is generally considered to be the first line
therapy for patients with type 2 diabetes. The results of
the DURATION -4 study showed that exenatide QW
was noninferior to metformin and that metformin and
exenatide QW provided similar improvements in glycemic
control (-1.5% vs -1.5%) in treatment-naïve patients, with
the added benefits of weight reduction and minimal risk
of hypoglycemia [25]. The results of the present analysis
reaffirm the original results; for most goals, both therapies
had similar effects.
The ABI [95% CI] significantly favored exenatide QW
over metformin for the glycemic goals of HbA1c ≤6.5%
and fasting blood glucose (FBG) <6.99 mmol/L (126 mg/
dL) (12% [3%, 20%] and 12.9% [4%, 22%], respectively),
with associated NNTs of 9 and 8, respectively (Table 3
and Figure 1). None of the composite goals showed a
significant difference between the two therapies.
Exenatide QW vs sitagliptin
In two of the Phase 3 studies, DURATION-2 and
DURATION-4, the safety and efficacy of exenatide QW
was compared to sitagliptin in two different popula-
tions of patients (metformin co-treatment or treatment-
naïve, respectively). The primary outcome of the two
trials showed that exenatide QW was superior to
sitagliptin in reducing HbA1c, with LS mean reductions
in HbA1c of -1.5% (exenatide QW) vs -0.9% (sitagliptin)
in DURATION-2, and -1.5% (exenatide QW) vs -1.2%
(sitagliptin) in DURATION-4 [23,25].
Table 2 Baseline demographics
DURATION-4* DURATION-2† DURATION-3‡
ExQW Met Sita Pio EQW Sita Pio ExQW IG
N 248 246 163 163 160 166 165 233 223
Sex (Male) (%) 56 63 58 60 56 52 48 52 55
Race (%)
American Indian or Alaska Native <1 1 1 0 0 2 0 0 0
Asian 22 21 20 21 23 25 24 6 6
Black or African American 3 5 2 3 12 12 8 1 >1
Hispanic 7 9 8 9 31 30 27 12 9
Other 0 <1 0 0 1 1 2 0 0
White 68 65 69 68 33 30 39 82 85
Age (y) 54 ± 11 54 ± 11 52 ± 11 55 ± 11 52 ± 10 52 ± 11 53 ± 10 58 ± 10 58 ± 9
Duration of diabetes (y) 3 ± 3 3 ± 4 3 ± 4 3 ± 4 6 ± 5 5 ± 5 6 ± 6 8 ± 6 8 ± 6
Baseline weight (kg) 87 ± 19 86 ± 20 89 ± 19 86 ± 18 89 ± 20 87 ± 20 88 ± 21 91 ± 19 91 ± 16
Baseline BMI (kg/m2) 31 ± 5 31 ± 5 32 ± 5 31 ± 5 32 ± 5 32 ± 5 33 ± 6 32 ± 5 32 ± 5
Baseline HbA1c (%) 8.5 ± 1.2 8.6 ± 1.2 8.5 ± 1.3 8.5 ± 1.2 8.6 ± 1.2 8.5 ± 1.2 8.5 ± 1.1 8.3 ± 1.1 8.3 ± 1.0
Baseline FBG (mmol/L) 9.9 ± 2.9 10.0 ± 3.4 9.7 ± 2.6 9.8 ± 3.0 9.2 ± 2.9 9.1 ± 2.5 9.1 ± 2.4 9.9 ± 2.5 9.7 ± 2.7
Baseline SBP (mm Hg) 129 ± 12 129 ± 15 130 ± 13 131 ± 15 126 ± 14 126 ± 14 127 ± 14 135 ± 17 133 ± 16
Baseline LDL (mmol/dL) 3.1 ± 1.1 2.9 ± 0.9 3.0 ± 0.9 3.1± 1.0 2.6 ± 0.8 2.8 ± 0.9 2.9 ± 1.0 2.7 ± 0.9 2.7 ± 0.9
Background therapy (n)
Metformin 160 166 165 164 157
Diet and Exercise 248 246 163 163
Metformin + Sulfonylurea 69 66
*†‡Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once-Weekly-4, -2, -3 [23-25].
Values are shown as mean ± SD.
BMI , body mass index; DBP, diastolic blood pressure; ExQW, exenatide QW; HDL, high density lipoprotein cholesterol; IG, insulin glargine; Met, metformin; Pio,
pioglitazone; Sita, sitagliptin.
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HbA1c with exenatide QW compared to sitagliptin, a
larger percentage of patients treated with exenatide QW
compared to sitagliptin attained the HbA1c goals of <7%
or ≤6.5% (Table 3). The largest benefit for the use of
exenatide QW vs sitagliptin was observed in attaining
the goal of HbA1c <7% (in DURATION-2) where the
ABI (95% CI) was 30.9% (20%, 41%). The ABI favored
exenatide QW over sitagliptin for each HbA1c and FBG
single goal and for all of the composite goals in both
studies (Figure 2). The associated NNTs for each of
the goals were generally similar in both DURATION-2
and -4 studies (Table 3). Five patients would need to
be treated with exenatide QW rather than sitagliptin for
26 weeks to have one additional patient reach an HbA1c
goal of ≤6.5%. Similarly, the NNT for one additional
patient to attain the composite goal of HbA1c ≤6.5%
without weight gain or hypoglycemia was 5 to 6. In both
studies comparing exenatide QW and sitagliptin, the NNT
was 10 for the composite goal combining HbA1c <7%,
SBP <130 mm Hg, and LDL <2.59 mmol/L.Exenatide QW vs pioglitazone
The DURATION-2 and DURATION-4 studies also com-
pared exenatide QW with pioglitazone. The reduction in
HbA1c with exenatide QW treatment was consistent in
both trials (-1.5%), while the reduction in HbA1c with
pioglitazone treatment was -1.2% in DURATION-2 (on a
background of metformin-treated patients) and -1.6% in
DURATION-4 (in a drug-naïve patient population); re-
sulting in exenatide QW superiority over pioglitazone in
DURATION-2 and lack of noninferiority in DURATION-4.
The ABI for both HbA1c single goals favored exenatide
QW over pioglitazone in both studies; however, the results
were not significant in the DURATION-4 study (Table 3
and Figure 3). The ABI for FBG in the DURATION-4
study slightly favored pioglitazone (-1.3% [-12%, 9%]) but
the result was also not significant (Figure 3). Although the
primary result of the DURATION-4 study failed to demon-
strate noninferiority of exenatide QW vs pioglitazone with
regard to HbA1c reduction, the ABI for the composite
goals of HbA1c at target (<7% or ≤6.5%) with no weight
gain or hypoglycemia, significantly favored exenatide QW






















ExQW 61.6% 58.6% 59.0%
(237) (157) (222)
Met 54.8% 6.8% 15
(239) (-2%, 15%) (7, ∞, -49)
Sita 41.4% 20.2% 5 27.7% 30.9% 4
(152) (10%, 30%) (4, 10) (155) (20%, 41%) (3, 5)
Pio 58.5% 3.0% 34 43.4% 15.2% 7
(157) (-7%, 13%) (8, ∞, -15) (159) (4%, 26%) (4, 24)
IG 46.5% 12.5% 8
(215) (3%, 22%) (5, 32)
HbA1c ≤6.5%
ExQW 48.2% 38.8% 42.2%
(247) (160) (232)
Met 36.2% 12.0% 9
(243) (3%, 20%) (5, 31)
Sita 24.5% 23.7% 5 14.6% 24.2% 5
(163) (14%, 32%) (4, 7) (164) (15%, 33%) (3, 7)
Pio 40.9% 7.3% 14 26.1% 12.7 8
(159) (-3%, 17%) (6, ∞, -38) (165) (3%, 23%) (5, 40)
IG 28.1% 14.1% 8
(221) (5%, 23%) (5, 19)
No Weight Gain
ExQW 72.6% 78.1% 84.1%
(248) (160) (233)
Met 76.8% -4.2% -24
(246) (-12%, 3%) (29, ∞, -9)
Sita 65.0% 7.6% 14 59.6% 18.5% 6
(163) (-1%, 17%) (6, ∞, -69) (166) (8%, 28%) (4, 12)
Pio 36.8% 35.8% 3 24.2% 53.9% 2
(163) (26%, 45%) (3, 4) (165) (44%, 62%) (2, 3)
IG 33.2% 50.9% 2
(223) (43%, 58%) (2, 3)
Any Weight Loss
ExQW 68.5% 76.9% 79.0%
(248) (160) (233)
Met 72.8% -4.3% -24
(246) (-12%, 4%) (27, ∞, -9)
Sita 55.9% 12.7% 8 59.0% 17.9% 6
(163) (3%, 22%) (5, 32) (166) (8%, 27%) (4, 13)
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Table 3 Absolute benefit increase and number needed to treat by comparator and study (Continued)
Pio 33.1% 35.4% 3 21.2% 55.7% 2
(163) (26%, 44%) (3, 4) (165) (46%, 64%) (2, 3)
IG 30.5% 48.5% 3
(223) (40%, 56%) (2, 3)
No Major/Minor Hypoglycemia
ExQW 98.0% 98.8% 88.4%
(248) (160) (233)
Met 100.0% -2.0% -50
(246) (-5%, 0%) (∞, -22)
Sita 100.0% -2.0% -50 97.0% 1.8% 56
(163) (-5%, 1%) (175, ∞, -22) (166) (-2%, 6%) (17, ∞, -56)
Pio 100.0% -2.0% -50 98.8% 0 N/A
(163) (-5%, 1%) (175, ∞, -22) (165) (-3%, 3%)
IG 69.5% 18.9% 6
(223) (12%, 26%) (4, 9)
SBP<130 mm Hg
ExQW 39.7% 56.9% 25.3%
(126) (58) (154)
Met 25.0% 14.7% 7
(124) (3%, 26%) (4, 32)
Sita 31.2% 8.5% 12 34.8% 22.1% 5
(93) (-4%, 21%) (5, ∞, -23) (66) (5%, 38%) (3, 22)
Pio 32.2% 7.5% 14 39.1% 17.8% 6
(87) (-6%, 20%) (5, ∞, -18) (69) (0%, 34%) (3, 244)
IG 21.3% 4.0% 25
(136) (-6%, 14%) (8, ∞, -17)
FBG <6.99 mmol/L (<126 mg/dL)
ExQW 47.0% 54.9% 38.6%
(219) (122) (215)
Met 34.1% 12.9% 8
(217) (4%, 22%) (5, 27)
Sita 20.8% 26.2% 4 27.4% 27.5% 4
(144) (16%, 35%) (3, 7) (135) (16%, 38%) (3, 7)
Pio 48.3% -1.3% -77 44.5% 10.4% 10
(145) (-12%, 9%) (11, ∞, -9) (137) (-2%, 22%) (5, ∞, -57)
IG 51.5% -12.9% -8
(200) (-22%, -3%) (-5, -30)
LDL <2.59 mmol/L (100 mg/dL)
ExQW 20.2% 29.8% 32.3%
(168) (84) (130)
Met 23.1% -2.9% -35
(160) (-12%, 6%) (17, ∞, -9)
Sita 13.8% 6.4% 16 21.6% 8.2% 13
(109) (-3%, 15%) (7, ∞, -33) (97) (-4%, 21%) (5, ∞, -22)
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Table 3 Absolute benefit increase and number needed to treat by comparator and study (Continued)
Pio 13.0% 7.2% 14 19.4% 10.4% 10
(115) (-2%, 16%) (7, ∞, -52) (103) (-2%, 23%) (5, ∞, -53)
IG 15.3% 17.0% 6
(124) (7%, 27%) (4, 15)
Composite Goals
HbA1c <7.0%, No Weight Gain, No Hypoglycemia
ExQW 48.4% 48.1% 46.8%
(248) (160) (233)
Met 48.0% 0.4% 250
(246) (-8%, 9%) (11, ∞, -12)
Sita 34.4% 14.0% 8 22.3 25.8% 4
(163) (4%, 23%) (5, 24) (166) (16%, 35%) (3, 7)
Pio 21.5% 26.9% 4 9.7% 38.4% 3
(163) (18%, 35%) (3, 6) (165) (29%, 47%) (3, 4)
IG 13.0% 33.8% 3
(223) (26%, 41%) (3, 4)
HbA1c ≤6.5%, No Weight Gain, No Hypoglycemia
ExQW 39.1% 32.5% 30.5%
(248) (160) (233)
Met 32.9% 6.2% 17
(246) (-2%, 15%) (7, ∞, -44)
Sita 19.6% 19.5% 6 12.0% 20.5% 5
(163) (11%, 28%) (4, 10) (166) (12%, 29%) (4, 9)
Pio 17.2% 21.9% 5 5.5% 27.0% 4
(163) (13%, 30%) (4, 8) (165) (19%, 35%) (3, 6)
IG 9.4% 21.1% 5
(223) (14%, 28%) (4, 8)
HbA1c<7%, SBP <130 mm Hg, LDL <2.59 mmol/L
ExQW 15.0% 22.6% 17.7%
(246) (159) (231)
Met 13.4% 1.6% 63
(246) (-5%, 8%) (13, ∞, -22)
Sita 5.0% 10.0% 10 11.6% 11.0% 10
(160) (4%, 16%) (7, 25) (164) (3%, 19%) (6, 36)
Pio 8.7% 6.3% 16 14.6% 8.0% 13
(161) (0%, 12%) (9, ∞, -285) (164) (-1%, 16%) (7, ∞, -197)
IG 10.3% 7.4% 14
(223) (1%, 14%) (8, 101)
HbA1c ≤6.5%, SBP<130 mm Hg, LDL <2.59 mmol/L
ExQW 12.9% 16.9% 12.9%
(248) (160) (232)
Met 7.7% 5.2% 20
(246) (0%, 11%) (10, ∞, -490)
Sita 4.3% 8.6% 12 6.1% 10.8% 10
(163) (3%, 14%) (8, 34) (165) (4%, 18%) (6, 26)
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Table 3 Absolute benefit increase and number needed to treat by comparator and study (Continued)
Pio 6.2% 6.7% 15 9.1% 7.8% 13
(161) (1%, 12%) (9, 152) (165) (0%, 15%) (7, 220 )
IG 5.8% 7.1% 15
(223) (2%, 13%) (8, 58)
ABI, Absolute Benefit Increase; NNT, number needed to treat;
NNT compares ExQW with indicated comparator; an infinity limit (∞) is shown for the 95% CI of the NNT if the 95% CI of the ABI contains zero;
N refers to subjects not at goal at baseline.
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≤6.5% composite goal: 21.9% [13%, 30%]) with an associ-
ated NNT of 4 and 5, respectively. The NNT for these
same composite goals was 3 and 4, respectively in the
DURATION-2 study.
Exenatide QW vs insulin glargine
The efficacy and safety of exenatide QW vs insulin
glargine was compared in the DURATION-3 study
resulting in a reduction in HbA1c of -1.5% for exenatide
QW and -1.3% for insulin glargine [24]. In the current
analysis, a larger percentage of patients in the exenatide
QW group reached the recommended HbA1c goals of
<7.0% and ≤6.5% compared to patients in the insulin
group (Table 3). The resulting ABI was 12.5% (3%, 22%)
and 14.1% (5%, 23%), respectively, with an NNT of 8 for
both goals. A larger percentage of patients in the insulinFigure 1 Absolute Benefit Increase (ABI) of Exenatide QW (ExQW) vs M
metformin. ABI = 0% indicates no benefit; ABI <0% indicates metformin prglargine group attained the FBG goal, resulting in an ABI
of -12.9% (-22%, -3%) and an associated NNT of -8
(Table 3, Figure 4). Exenatide QW was significantly fa-
vored over insulin glargine for attaining all four composite
goals (Figure 4). Of all of the composite goals, the largest
benefit of exenatide QW use was observed for the goal
of HbA1c <7% without weight gain or hypoglycemia with
an ABI of 33.8% (26%, 41%) and an associated NNT of 3
(Figure 4).
Adverse events
The most frequent adverse events occurring in patients
treated with exenatide QW, metformin, sitagliptin, pioglit-
azone, or insulin glargine in each of the three studies is
listed in Table 4. Across the studies, the most common ad-
verse events for any of the treatments in all studies were
nausea, diarrhea, injection site reactions, nasopharyngitis,etformin. Forest plot depicts the ABI (%) ± 95% CI of ExQW vs
ovides a benefit vs ExQW.
Figure 2 Absolute Benefit Increase (ABI) of Exenatide QW (ExQW) vs Sitagliptin. Forest plot depicts the ABI (%) ± 95% CI of ExQW vs
sitagliptin. Data comparing ExQW to sitagliptin originate from DURATION-2 (filled circles) and DURATION-4 (open circles) studies. ABI = 0%
indicates no benefit; ABI <0% indicates sitagliptin provides a benefit vs ExQW.
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withdrawal was 7%, 3%, and 4% (exenatide QW, sitagliptin,
and pioglitazone, respectively) in DURATION-2, 5% and
1% (exenatide QW and insulin glargine, respectively) in
DURATION-3, and 2%, 2%, 1% and 3% (exenatide QW,
metformin, sitagliptin, and pioglitazone, respectively) in
DURATION-4.
Discussion
The selection of an optimal agent for treatment of T2DM
can pose a challenge given that many therapeutic options
are effective in reducing HbA1c, an indicator of blood glu-
cose control. However, not all therapies reduce HbA1c
sufficiently to achieve therapeutic goals. The recent Stan-
dards in Medical Care in Diabetes from the ADA has
outlined a set of target goals believed to favorably affect
the health outcomes of patients with T2DM [11]. The
guidelines also suggest that individual preferences and
comorbidities should be taken into consideration whenchoosing a therapy. Factors such as weight loss (or at least
no weight gain) and the avoidance of hypoglycemia are
important considerations. Indeed, in a patient survey
conducted in patients with T2DM, more than half of the
patients indicated that they would be willing to take an in-
jectable once-weekly medication if the medication pro-
moted weight loss or helped avoid weight gain [31].
Hypertension and dyslipidemia are other major modifiable
risk factors for CVD commonly associated with T2DM.
As such, they contribute to the already increased risk of
CVD. Beyond glycemic control, the improvement of such
CV risk factors represents an added advantage to thera-
pies providing such benefits.
Achievement of glycemic goals
This analysis compared the ability of exenatide QW vs
metformin, sitagliptin, pioglitazone, or insulin glargine
to assist patients in achieving ADA-recommended target
goals. NNTs were calculated as a metric to assess how
Figure 3 Absolute Benefit Increase (ABI) of Exenatide QW (ExQW) vs Pioglitazone. Forest plot depicts the ABI (%) ± 95% CI of ExQW vs
pioglitazone. Data comparing ExQW to pioglitazone originate from DURATION-2 (filled circles) and DURATION-4 (open circles) studies. ABI = 0%
indicates no benefit; ABI <0% indicates pioglitazone provides a benefit vs ExQW.
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apy rather than another to allow one additional patient
to reach a target. Compared to the other therapies ex-
amined, exenatide QW assisted a larger proportion of
patients who were not already at HbA1c ≤6.5% or <7%
at baseline in reaching the target goal after 26 weeks of
treatment. The ABI for the goal of HbA1c ≤6.5% signifi-
cantly favored exenatide QW over metformin, sitagliptin,
pioglitazone, or insulin glargine in all studies except for
DURATION-4 where the ABI for exenatide QW vs pio-
glitazone favored exenatide QW, but did not reach stat-
istical significance. Contrary to the HbA1c goals, insulin
was significantly favored over exenatide QW for the FBG
goal. One reason for the discrepancy between the two gly-
cemic endpoints is that the insulin was titrated according
to a FBG target. Thus, the dosage of insulin glargine was
raised until the FBG target was met, thereby contributing
to bias. In addition, FBG is a short-term measure of blood
glucose levels while HbA1c indirectly measures an average
glucose concentration over a prolonged period of time. As
insulin glargine is a titrated, long-acting basal insulin, itmay function well to reduce fasting glucose levels but
permit higher postprandial excursions leading to a larger
average glucose concentration compared to the glucose-
dependent activity of exenatide QW [32,33].
The results of this analysis provide information to assist
in personalization of therapy. The NNT for the HbA1c
≤6.5% goal was 8 when exenatide QW was compared to
insulin glargine. However, for the alternate glycemic goal,
FBG <6.99 mmol/L, the NNT was -8 for exenatide QW vs
insulin glargine (favoring insulin glargine). This means
that, in patients for whom FBG may be the more impor-
tant clinical concern, treatment of 8 patients with insulin
glargine rather than exenatide QW would allow one add-
itional patient to reach a FBG goal. However, in patients
wishing to achieve the HbA1c target (≤6.5%), 8 patients
would need to be treated with exenatide QW rather than
insulin to allow one additional patient to achieve the goal.
Control of cardiovascular risk factors
Although the main focus of treatment is a reduction in
hyperglycemia, improved glycemic control is associated
Figure 4 Absolute Benefit Increase (ABI) of Exenatide QW (ExQW) vs Insulin Glargine. Forest plot depicts the ABI (%) ± 95% CI of ExQW vs
insulin glargine. ABI = 0% indicates no benefit; ABI <0% indicates insulin glargine provides a benefit vs ExQW.
Table 4 Incidence of adverse events >5% in any treatment group in any study
DURATION-4* DURATION-2† DURATION-3‡
ExQW Met Sita Pio ExQW Sita Pio ExQW IG
(N = 248) (N = 246) (N = 163) (N = 163) (N = 160) (N = 166) (N = 165) (N = 233) (N = 223)
Arthralgia (%) 5 1 2 3 3 5 2 4 3
Back pain (%) 2 6 3 4 4 4 3 4 2
Constipation (%) 9 3 3 2 6 2 1 3 2
Diarrhea (%) 11 13 6 4 18 10 7 9 4
Dyspepsia (%) 7 3 2 5 4 4 2 3 1
Fatigue (%) 1 0 1 1 6 0 3 3 <1
Headache (%) 8 12 9 8 9 9 4 10 7
Hypertension (%) 1 1 2 7 3 3 1 2 3
Injection site nodule (%) 11 10 7 4 3 1 1 6 0
Injection site pruritus (%) 4 2 1 1 5 5 1 1 <1
Nasopharyngitis (%) 8 5 10 9 4 2 3 13 18
Nausea (%) 11 7 4 4 24 10 5 13 1
Peripheral edema (%) 0 <1 1 7 1 3 8 0 0
Sinusitis (%) <1 <1 0 2 3 1 7 1 2
Urinary tract infection (%) 1 2 1 1 6 5 4 1 <1
Upper-respiratory tract infection (%) 3 3 1 2 4 9 10 2 1
Vomiting (%) 5 3 2 3 11 2 3 4 1
ND, not determined.
Data are% of intent-to-treat population.
*†‡Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once-Weekly-4, -2, -3 [23-25].
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medications, and these CV risk factors also reduce pa-
tients’ quality of life. Unlike medications that promote
weight gain or increase the risk of hypoglycemia, GLP-1
receptor agonists are generally associated with weight loss
and minimal risk of hypoglycemia. In the current analysis,
examination of the weight and hypoglycemia effects
of exenatide QW was assessed as a composite goal of
HbA1c <7% with no weight gain and no hypoglycemia.
Exenatide QW provided a significant ABI for achieving
this composite goal compared to sitagliptin, pioglitazone,
and insulin glargine, with NNTs as low as 3 (vs pioglit-
azone and insulin glargine). Across the three studies,
exenatide QW assisted between 47 and 48% of patients
who were not already at this composite goal in achieving
the goal after 26 weeks. The comparators assisted between
10% (pioglitazone) and 48% (metformin) of patients in
achieving this goal. These data are consistent with an ana-
lysis pooling 804 patients treated with exenatide QW dur-
ing the DURATION trials, where 50% of patients treated
with exenatide QW achieved the goal of HbA1c <7% with
no weight gain and no hypoglycemia after 24-30 weeks
[34]. A recent meta-analysis study similarly showed that
1.8 mg liraglutide once daily assisted 40% of patients in
achieving the goal of HbA1c <7% with no weight gain and
no hypoglycemia [35]. The meta-analysis additionally
showed that the twice-daily formulation of exenatide
assisted 25% of patients in achieving the composite goal,
which was a higher percentage than sulfonylureas (8%),
thiazolidinediones (6%), insulin glargine (15%), sitagliptin
(11%), and placebo (8%) [35].
The magnitudes of the NNT values obtained for some
goals reflect key differences between therapies. To put
NNT values into better perspective, an NNT of 1 would
mean that every patient treated would reach the speci-
fied goal. The significant NNTs for the composite goal
of HbA1c <7% with no weight gain and no hypoglycemia
ranged from 3 when exenatide QW was compared to in-
sulin glargine and pioglitazone (in DURATION-2) to 8
when exenatide QW was compared to sitagliptin in
DURATION-4. However, an NNT of 250 was observed
for exenatide QW compared to metformin suggesting no
greater benefit of either treatment in achieving this com-
posite goal. As commonly used, an NNT of 20 or less is
generally sufficient to justify the choice of a clinical inter-
vention in the absence of a more significant clinical harm
[30,36].
A second composite goal, based on findings from the
Steno-2 study, highlighted the importance of HbA1c,
blood pressure, and lipids in the reduction of CV risk in
patients with T2DM [4]. The Steno-2 study identified
the benefits of a multifactorial intervention strategy by
demonstrating an approximately 50% reduction in risk
of CV and microvascular events by targeting multiplerisk factors with intensified treatment [4]. Despite the
importance of such a multi-targeted therapeutic ap-
proach, the NHANES analysis reported that between
1999 and 2004, only 13% of surveyed diabetes patients
achieved a composite goal of HbA1c <7.0%, blood pres-
sure <130/80 mm Hg, and total cholesterol <5.17 mmol/L
(<200 mg/dL) [37]. The current analysis used the individ-
ual ADA-suggested goals to define a composite goal of
HbA1c <7%, SBP <130 mm Hg, and LDL <2.59 mmol/L
(<100 mg/dL). The results showed that across the three
studies, between 23% and 15% of patients who were
not already at the goal at baseline reached the compos-
ite goal using exenatide QW, slightly more than observed
in the NHANES report. Comparators assisted between
15% (pioglitazone, DURATION-2) and 5% (sitagliptin,
DURATION-4) of patients in reaching the composite goal
which is in line with NHANES estimates for this compos-
ite. The ABI for this goal significantly favored exenatide
QW compared to sitagliptin or insulin glargine with
NNTs of 10 and 14, respectively.
Limitations and additional studies
Limitations of the current analysis include its retrospect-
ive, post hoc design and the small sample size. Common
NNT analyses generally examine larger populations over
a longer time period to observe a particular rare but
clinically important outcome in a significant number of
patients [28,38,39]. A study of the attainment of thera-
peutic goals and ABI calculations in a large, real-world
population would be a useful follow-up to this study.
Since exenatide QW was approved in 2011 in Europe
and in 2012 in the United States, substantive real-world
data are not yet available. Furthermore, the second com-
posite goal (HbA1c <7%, SBP <130 mm Hg, and LDL
<2.59 mmol/L) focused on a single lipid parameter, whereas
other lipid parameters (eg, triglycerides, high-density lipo-
protein cholesterol, lipoprotein subfractions) and endothe-
lial function also influence CV risk and have been shown to
be affected by treatment with exenatide QW, but evaluation
of these variables were beyond the scope of the current in-
vestigation [40-42]. In addition, NNTs were calculated in
the absence of a number needed to harm as the common
adverse events associated with each of the therapies exam-
ined here were therapy-specific.
The current analysis comparing glucose-lowering ther-
apies does not take into account differential cost or con-
venience factors; nor does it consider patient or physician
perception of the different routes of administration. In
addition, although the composite goals examined pro-
vide a clinically relevant combination of treatment targets,
a single component of the composite could drive the re-
sult. For example, pioglitazone and insulin glargine are
often associated with weight gain and therefore would
not be favored in achieving composite goals containing a
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is a glucose-independent, titrated medication, there is a
greater risk for hypoglycemia which would lead to an un-
favorable comparison with a glucose-dependent therapy
(such as exenatide QW) in a composite goal including no
hypoglycemia.
Although surrogate endpoints are not typically used
in NNT assessments, the ability to achieve therapeutic
goals is clinically important and relevant for short-term
treatment decisions. Indeed, in a recent 1-year study with
liraglutide, the NNT to achieve a loss of 10% of total body
weight was calculated as 2 with liraglutide compared to 7
for placebo [43]. While the NNTs calculated in the
current analysis reflect the attainment of a glycemic goal
over a relatively short period of time (26 weeks), data has
suggested that early intensive glucose control, even for a
short period of time, might have a significant effect on CV
events later in life, the so called legacy effect [44-46]. The
ongoing EXSCEL (Exenatide Study of Cardiovascular
Event Lowering, clinical trial number NCT01144338) trial
will measure the time to the first confirmed CV event. In
addition, the results of the trial are expected to further
clarify the ability of exenatide QW to assist patients in
reaching ADA-recommended goals and examine the pre-
sumption that reaching these goals correlates with a re-
duction of CV risk.
Conclusions
This analysis compares the ability of exenatide QW vs com-
monly used glucose-lowering therapies representative of
other drug classes (eg, biguanides, dipeptidyl peptidase-4
inhibitors, thiazolidinediones, or basal insulin) to assist
patients in reaching important therapeutic goals. The re-
sults from clinical trials indicate that for the majority of
ADA-recommended therapeutic goals, exenatide QW as-
sists more patients in reaching the goal than treatment with
sitagliptin, pioglitazone, or insulin glargine. The NNTs pro-
vided here indicate that fewer patients need to be treated
with exenatide QW than with sitagliptin, pioglitazone or
insulin glargine to attain the same composite goal of gly-
cemic control without weight gain or hypoglycemia. The
attainment of ADA-recommended goals promise to pro-
vide a clinical benefit in the reduction of CV risk and on-
going CV clinical trials are expected to provide answers as
to whether reaching target goals are reliable predictors of
reduced morbidity and mortality.
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